Opinion
Video
Author(s):
Innovative therapies for ovarian cancer, including engineered T cells and antibody-drug conjugates, show promise in improving patient outcomes.
Video content is prompted by the following: Future Potential of Novel Therapeutic Approaches
Key Discussion Points:
Notable Insights:
“CAR T, the limitation with ovary is that a lot of our proteins are intracellular proteins...but CAR-NK may be a completely different ballgame for us.”
“The challenge with [cellular therapies] is...you can’t leave people just sitting around for 2 months waiting for manufacture of cells who have kind of actively growing disease. It’s not ethical.”
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.